Cancer Monoclonal Antibodies Global Market Report 2023
Report Highlights
Including: 1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin); Rituximab (Rituxan); Trastuzumab (Herceptin); Cetuximab (Erbitux); Panitumumab (Vectibix)
2) By Application: Breast Cancer; Blood Cancer; Liver Cancer; Brain Cancer; Colorectal Cancer
3) By End User: Hospitals And Clinics; Research Laboratories; Pharmacies
Covering: Amgen; Bristol Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; Genmab AS
Cancer Monoclonal Antibodies Global Market Report 2023 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cancer monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia – Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description:
Where is the largest and fastest growing market for cancer monoclonal antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2022 |
| Forecast period considered | 2022-2032 |
| Units considered | $ Billion |
| Segments covered | By Monoclonal Antibody Therapies, By Application, By End User |
| Industry covered | Pharmaceuticals |
| Regions covered | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Countries covered | Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA |
| Companies studied |
|
Scope
Markets Covered:
- By Monoclonal Antibody Therapies: Bevacizumab (Avastin); Rituximab (Rituxan); Trastuzumab (Herceptin); Cetuximab (Erbitux); Panitumumab (Vectibix); Other Monoclonal Antibody Therapies
- By Application: Breast Cancer; Blood Cancer; Liver Cancer; Brain Cancer; Colorectal Cancer; Other Applications
- By End User: Hospitals And Clinics; Research Laboratories; Pharmacies; Other End Users
Companies Mentioned: Amgen; Bristol Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genmab AS
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
- Table 1 : Global Historic Market Growth, 2017-2022, $ Billion
- Table 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
- Table 3 : Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 4 : Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 5 : Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 6 : Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 7 : Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 8 : Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 9 : China, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 10 : India, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 11 : Japan, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 12 : Australia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 13 : Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 14 : South Korea, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 15 : Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 16 : UK, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 17 : Germany, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 18 : France, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 19 : Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 20 : Russia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 21 : North America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 22 : USA, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 23 : South America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 24 : Brazil, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 25 : Middle East, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 26 : Africa, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 27 : Amgen Financial Performance
- Table 28 : Bristol Myers Squibb Company Financial Performance
- Table 29 : Eli Lilly and Company Financial Performance
- Table 30 : F. Hoffmann-La Roche Ltd Financial Performance
- Table 31 : Genmab AS Financial Performance
- Figure 1 : Global Historic Market Growth, 2017-2022, $ Billion
- Figure 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
- Figure 3 : Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 4 : Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 5 : Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 6 : Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 7 : Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 8 : Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 9 : China, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 10 : India, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 11 : Japan, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 12 : Australia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 13 : Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 14 : South Korea, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 15 : Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 16 : UK, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 17 : Germany, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 18 : France, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 19 : Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 20 : Russia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 21 : North America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 22 : USA, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 23 : South America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 24 : Brazil, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 25 : Middle East, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 26 : Africa, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 27 : Amgen Financial Performance
- Figure 28 : Bristol Myers Squibb Company Financial Performance
- Figure 29 : Eli Lilly and Company Financial Performance
- Figure 30 : F. Hoffmann-La Roche Ltd Financial Performance
- Figure 31 : Genmab AS Financial Performance
The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Similar Reports from TBRC (Publisher)
Cancer Monoclonal Antibodies Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change
Including: 1) By Monoclonal Antibody Therapies: Avastin; Herceptin; Keytruda; Opdivo; Darzalex; Perjeta; Others
2) By Application: Breast Cancer; Blood Cancer; Lung Cancer; Brain Tumor; Colorectal Cancer; Cervical Cancer; Gastric Cancer; Others
3) By End-User : Hospitals; Research Laboratories; Others
Covering: F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Bristol Myers Squibb Company; Johnson & Johnson; Amgen Inc.
Cancer Monoclonal Antibodies ...
Cancer Monoclonal Antibodies Global Market Report 2022
Including: 1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin); Rituximab (Rituxan); Trastuzumab (Herceptin); Cetuximab (Erbitux); Panitumumab (Vectibix); Others
2) By Application: Breast Cancer; Blood Cancer; Liver Cancer; Brain Cancer; Colorectal Cancer; Others
3) By End User: Hospitals And Clinics; Research Laboratories; Pharmacies; Others
Covering: Amgen; Bristol Myers Squibb Company; Eli Lilly and Company; F.Hoffmann-La Roche Ltd.; Genmab AS; GlaxoSmithKline
Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
Including: 1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin); Rituximab (Rituxan); Trastuzumab (Herceptin); Cetuximab (Erbitux); Panitumumab (Vectibix); Others
2) By Application: Breast Cancer; Blood Cancer; Liver Cancer; Brain Cancer; Colorectal Cancer; Others
3) By End User: Hospitals And Clinics; Research Laboratories; Pharmacies; Others
Covering: Amgen; Bristol Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genmab AS
Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change
Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change
Including: 1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin); Rituximab (Rituxan); Trastuzumab (Herceptin); Cetuximab (Erbitux); Panitumumab (Vectibix); Others
2) By Application: Breast Cancer; Blood Cancer; Liver Cancer; Brain Cancer; Colorectal Cancer; Others
Covering: Amgen; Bristol Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genmab AS
Cancer Monoclonal ...